GlaxoSmithKline (GSK) is investing more than CA$30m (€21m) to add dermatology product manufacturing capabilities and create 70 jobs at a Canadian plant. Expansion of the Mississauga, Ontario plant protects the jobs of 300 people, adds another 70 positions and extends production capabilities at the facility. In particular, the addition of manufacturing capabilities for dermatology products moves the plant into a whole new area of GSK’s business.
